Late-differentiated effector neoantigen-specific CD8+ T cells are enriched in peripheral blood of non-small cell lung carcinoma patients responding to atezolizumab treatment

BACKGROUND: There is strong evidence that immunotherapy-mediated tumor rejection can be driven by tumor-specific CD8+ T cells reinvigorated to recognize neoantigens derived from tumor somatic mutations. Thus, the frequencies or characteristics of tumor-reactive, mutation-specific CD8+ T cells could...

Descripción completa

Detalles Bibliográficos
Autores principales: Fehlings, Michael, Jhunjhunwala, Suchit, Kowanetz, Marcin, O’Gorman, William E., Hegde, Priti S., Sumatoh, Hermi, Lee, Boon Heng, Nardin, Alessandra, Becht, Etienne, Flynn, Susan, Ballinger, Marcus, Newell, Evan W., Yadav, Mahesh
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6740011/
https://www.ncbi.nlm.nih.gov/pubmed/31511069
http://dx.doi.org/10.1186/s40425-019-0695-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6740011/
https://www.ncbi.nlm.nih.gov/pubmed/31511069
http://dx.doi.org/10.1186/s40425-019-0695-9

Ejemplares similares